May 15, 2020 / 1:31 PM / 22 days ago

BRIEF-U.S. FDA Approves Bristol Myers' Pomalyst For AIDS-Related And HIV-Negative Kaposi Sarcoma

May 15 (Reuters) - Bristol-Myers Squibb Co:

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES BRISTOL MYERS SQUIBB’S POMALYST® (POMALIDOMIDE) FOR AIDS-RELATED AND HIV-NEGATIVE KAPOSI SARCOMA

* BRISTOL-MYERS SQUIBB CO - AS DESCRIBED IN BOXED WARNINGS, POMALYST CAN CAUSE FETAL HARM & IS CONTRAINDICATED IN FEMALES WHO ARE PREGNANT

* BRISTOL-MYERS SQUIBB - POMALYST IS ONLY AVAILABLE THROUGH A RESTRICTED DISTRIBUTION PROGRAM, POMALYST REMS

* BRISTOL-MYERS SQUIBB CO - DEEP VEIN THROMBOSIS, PULMONARY EMBOLISM, MYOCARDIAL INFARCTION, STROKE CAN OCCUR IN PATIENTS TREATED WITH POMALYST Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below